Replies to post #477573 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

It's in todays PR.

[sumbuysumsell]

From today's EMA Acceptance PR:

Strengthening the submission is the 265 week (~5-year) Phase 2a trial investigating blarcamesine in mild-to-moderate Alzheimer’s disease, with interim preliminary data published in the peer-reviewed medical journal, Alzheimer’s & Dementia, titled: “A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study.”

https://finance.yahoo.com/news/blarcamesine-receives-ema-filing-acceptance-120000787.html